RG
APLS

Redmile Group’s Apellis Pharmaceuticals APLS Stock Holding History

Redmile Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-155,000
Closed -$9.11M – 66
2024
Q1 		$9.11M Buy
+155,000
New +$9.88M 0.33% 61

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Redmile Group's APLS Position: Q2 2024 in Review

Redmile Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 155,000 shares — an estimated $9.11M sold.

Redmile Group first reported a position in APLS in Q1 2024 and held it in 1 quarter. The position peaked at $9.11M in Q1 2024. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Redmile Group reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Redmile Group sold 155,000 Apellis Pharmaceuticals shares in Q2 2024, an estimated $9.11M.
  • Redmile Group first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Redmile Group's Apellis Pharmaceuticals position peaked at $9.11M in Q1 2024.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Redmile Group's 13F filing for Q2 2024, filed 14 Aug 2024.